Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evotec, Jain Foundation Expand Drug Screening Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Evotec, Jain Foundation Expand Drug Screening Pact

Evotec to provide screening of compound libraries in multiple assay formats

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Evotec AG and the Jain Foundation, Inc. have further extended their collaboration to include the screening of compound libraries in multiple assay formats to support Jain’s discovery efforts for dysferlinopathies, an inherited skeletal muscular dystrophy diseases. Financial terms were not disclosed.
 
Dr. Mario Polywka, chief operating officer of Evotec, said, “We are delighted to continue our relationship with the Jain Foundation and to be a part of this important step in dysferlin research. The progress to date and initiation of multiple screening programs is a major accomplishment for both organizations and demonstrates Evotec’s growing role in driving innovative and industrialized research in partnership with foundations such as the Jain Foundation working in rare diseases.”
 
Dr. Plavi Mittal, president and chief executive officer of Jain Foundation, added: “We are pleased with the progress of our project with Evotec to date, and are excited to move forward to the screening phase of our drug development program.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics